Psychedelics in psychiatric treatment: a literature review
DOI:
https://doi.org/10.12775/QS.2026.50.68013Keywords
psychedelics, psychedelic therapy, hallucinogens, depression, substance use disorders, PTSD, anxiety, psilocybin, MDMA, LSD, ketamineAbstract
Background: Psychedelic substances have been used for millennia in religious and healing contexts and have recently re-emerged as subjects of scientific interest due to advances in neuroscience and psychiatry. Research suggests that psychedelics may address limitations of conventional psychiatric treatments, particularly in disorders such as major depressive disorder, PTSD, substance use disorders, and anxiety disorders.
Aim: This article aims to critically review and synthesize current evidence on the neurobiological mechanisms, therapeutic efficacy, and safety profiles of selected psychedelic substances—psilocybin, LSD, MDMA, and ketamine—in the treatment of psychiatric disorders.
Materials and Methods: A literature review was conducted using databases including PubMed, Scopus, and Google Scholar. Clinical trials, meta-analyses, and reviews published in English between 2006 and 2025 were included. Studies addressing therapeutic outcomes, neurobiological mechanisms, and safety considerations of psychedelic-assisted therapies were analysed.
Results: In publications included in this literature review, psilocybin demonstrated robust antidepressant effects, benefits in substance use disorders, and reductions in anxiety following limited dosing sessions. MDMA-assisted psychotherapy showed strong efficacy in PTSD, with high remission rates. LSD exhibited promising effects in anxiety and substance use disorders. Ketamine produced rapid antidepressant and anti-suicidal effects in depression and showed potential in addiction and anxiety, although results in PTSD were mixed.
Conclusions: Psychedelic-assisted therapies represent a promising and scientifically credible expansion of psychiatric treatment options. While associated risks necessitate careful screening and clinical oversight, evidence supports their role as adjunctive or alternative interventions for selected patients, warranting further large-scale and long-term investigation.
References
Winkelman, M. (2019). Introduction: Evidence for entheogen use in prehistory and world religions. Journal of Psychedelic Studies, 3(2), 43–62. https://doi.org/10.1556/2054.2019.024
Vamvakopoulou, I. A., & Nutt, D. J. (2024). Psychedelics: From Cave Art to 21st-Century Medicine for Addiction. European addiction research, 30(5), 302–320. https://doi.org/10.1159/000540062
Kelmendi, B., Kichuk, S. A., DePalmer, G., Maloney, G., Ching, T. H. W., Belser, A., & Pittenger, C. (2022). Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon, 8(12), e12135. https://doi.org/10.1016/j.heliyon.2022.e12135
Nemu, D. (2019). Getting high with the most high: Entheogens in the Old Testament. Journal of Psychedelic Studies, 3(2), 117–132. https://doi.org/10.1556/2054.2019.004
Vamvakopoulou, I. A., & Nutt, D. J. (2024). Psychedelics: From Cave Art to 21st-Century Medicine for Addiction. European addiction research, 30(5), 302–320. https://doi.org/10.1159/000540062
Kelmendi, B., Kichuk, S. A., DePalmer, G., Maloney, G., Ching, T. H. W., Belser, A., & Pittenger, C. (2022). Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon, 8(12), e12135. https://doi.org/10.1016/j.heliyon.2022.e12135
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022). Psychedelics and Neural Plasticity: Therapeutic Implications. The Journal of neuroscience : the official journal of the Society for Neuroscience, 42(45), 8439–8449. https://doi.org/10.1523/JNEUROSCI.1121-22.2022
Inserra, A., Campanale, A., Cheishvili, D., Dymov, S., Wong, A., Marcal, N., Syme, R. A., Taylor, L., De Gregorio, D., Kennedy, T. E., Szyf, M., & Gobbi, G. (2022). Modulation of DNA methylation and protein expression in the prefrontal cortex by repeated administration of D-lysergic acid diethylamide (LSD): Impact on neurotropic, neurotrophic, and neuroplasticity signaling. Progress in neuro-psychopharmacology & biological psychiatry, 119, 110594. https://doi.org/10.1016/j.pnpbp.2022.110594
Khawam, E. A., Laurencic, G., & Malone, D. A., Jr (2006). Side effects of antidepressants: an overview. Cleveland Clinic journal of medicine, 73(4), 351–361. https://doi.org/10.3949/ccjm.73.4.351
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/nejmoa2032994
Kalfas, M., Taylor, R. H., Tsapekos, D., & Young, A. H. (2023). Psychedelics for treatment resistant depression: are they game changers? [Dataset]. https://doi.org/10.6084/m9.figshare.24541854.v1
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. Journal of psychopharmacology (Oxford, England), 29(3), 289–299. https://doi.org/10.1177/0269881114565144
Bogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., Rotrosen, J., Tonigan, J. S., & Worth, L. (2022). Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder. JAMA Psychiatry, 79(10), 953–962. https://doi.org/10.1001/jamapsychiatry.2022.2096
Psychedelic Therapy in the Treatment of Addiction; Korkmaz et alNur Damla Korkmaz, Ugur Cikrikcili, Merve Akan, & Emrah Yucesan. (2024). Psychedelic therapy in depression and substance use disorders. European Journal of Neuroscience/EJN. European Journal of Neuroscience, 60(2). https://doi.org/10.1111/ejn.16421
Davis, A. K., Levin, A. W., Nagib, P. B., Armstrong, S. B., & Lancelotta, R. L. (2023). Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD. BMJ open, 13(5), e068884. https://doi.org/10.1136/bmjopen-2022-068884
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020). Reviewing the Potential of Psychedelics for the Treatment of PTSD. The international journal of neuropsychopharmacology, 23(6), 385–400. https://doi.org/10.1093/ijnp/pyaa018
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of psychopharmacology (Oxford, England), 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513
Rucker, J. J., Jelen, L. A., Flynn, S., Frowde, K. D., & Young, A. H. (2016). Psychedelics in the treatment of unipolar mood disorders: a systematic review. Journal of psychopharmacology (Oxford, England), 30(12), 1220–1229. https://doi.org/10.1177/0269881116679368
Korkmaz, N. D., Cikrikcili, U., Akan, M., & Yucesan, E. (2024). Psychedelic therapy in depression and substance use disorders. The European journal of neuroscience, 60(2), 4063–4077. https://doi.org/10.1111/ejn.16421
Holze, F., Gasser, P., Müller, F., Dolder, P. C., & Liechti, M. E. (2023). Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Biological psychiatry, 93(3), 215–223. https://doi.org/10.1016/j.biopsych.2022.08.025
Krebs, T. S., & Johansen, P. Ø. (2012). Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. Journal of psychopharmacology (Oxford, England), 26(7), 994–1002. https://doi.org/10.1177/0269881112439253
Holze, F., Gasser, P., Müller, F., Strebel, M., & Liechti, M. E. (2024). LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up. The British journal of psychiatry : the journal of mental science, 225(3), 362–370. https://doi.org/10.1192/bjp.2024.99
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot'alora G, M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., Tzarfaty, K., … Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature medicine, 27(6), 1025–1033. https://doi.org/10.1038/s41591-021-01336-3
Sessa, B., Higbed, L., O'Brien, S., Durant, C., Sakal, C., Titheradge, D., Williams, T. M., Rose-Morris, A., Brew-Girard, E., Burrows, S., Wiseman, C., Wilson, S., Rickard, J., & Nutt, D. J. (2021). First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. Journal of psychopharmacology (Oxford, England), 35(4), 375–383. https://doi.org/10.1177/0269881121991792
Palhas, M., Corne, R., & Mongeau, R. (2025). Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction. Progress in neuro-psychopharmacology & biological psychiatry, 142, 111533. https://doi.org/10.1016/j.pnpbp.2025.111533
Feduccia, A. A., & Mithoefer, M. C. (2018). MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?. Progress in neuro-psychopharmacology & biological psychiatry, 84(Pt A), 221–228. https://doi.org/10.1016/j.pnpbp.2018.03.003
Danforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., Yazar-Klosinski, B., & Emerson, A. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology, 235(11), 3137–3148. https://doi.org/10.1007/s00213-018-5010-9
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A., Jr (2024). Ketamine in neuropsychiatric disorders: an update. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 49(1), 23–40. https://doi.org/10.1038/s41386-023-01632-1
Alnefeesi, Y., Chen-Li, D., Krane, E., Jawad, M. Y., Rodrigues, N. B., Ceban, F., Di Vincenzo, J. D., Meshkat, S., Ho, R. C. M., Gill, H., Teopiz, K. M., Cao, B., Lee, Y., McIntyre, R. S., & Rosenblat, J. D. (2022). Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. Journal of psychiatric research, 151, 693–709. https://doi.org/10.1016/j.jpsychires.2022.04.037
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., Kurian, B., Winokur, A., Fava, M., Manji, H., Drevets, W. C., & Van Nueten, L. (2016). A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. The American journal of psychiatry, 173(8), 816–826. https://doi.org/10.1176/appi.ajp.2016.16010037
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., Jr, & Sanacora, G. (2018). The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. The American journal of psychiatry, 175(2), 150–158. https://doi.org/10.1176/appi.ajp.2017.17040472
Kim, J. W., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2024). Ketamine: Mechanisms and Relevance to Treatment of Depression. Annual review of medicine, 75, 129–143. https://doi.org/10.1146/annurev-med-051322-120608
Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M., Choi, C. J. J., Basaraba, C. N., Pavlicova, M., & Levin, F. R. (2019). A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. The American journal of psychiatry, 176(11), 923–930. https://doi.org/10.1176/appi.ajp.2019.18101123
Azhari, N., Hu, H., O'Malley, K. Y., Blocker, M. E., Levin, F. R., & Dakwar, E. (2021). Ketamine-facilitated behavioral treatment for cannabis use disorder: A proof of concept study. The American journal of drug and alcohol abuse, 47(1), 92–97. https://doi.org/10.1080/00952990.2020.1808982
Du, R., Han, R., Niu, K., Xu, J., Zhao, Z., Lu, G., & Shang, Y. (2022). The Multivariate Effect of Ketamine on PTSD: Systematic Review and Meta-Analysis. Frontiers in psychiatry, 13, 813103. https://doi.org/10.3389/fpsyt.2022.813103
Almeida, T. M., Lacerda da Silva, U. R., Pires, J. P., Borges, I. N., Martins, C. R. M., Cordeiro, Q., & Uchida, R. R. (2024). Effectiveness of Ketamine for the Treatment of Post-Traumatic Stress Disorder - A Systematic Review and Meta-Analysis. Clinical neuropsychiatry, 21(1), 22–31. https://doi.org/10.36131/cnfioritieditore20240102
Taylor, J. H., Landeros-Weisenberger, A., Coughlin, C., Mulqueen, J., Johnson, J. A., Gabriel, D., Reed, M. O., Jakubovski, E., & Bloch, M. H. (2018). Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 43(2), 325–333. https://doi.org/10.1038/npp.2017.194
Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 142, 143–166. https://doi.org/10.1016/j.neuropharm.2018.05.012
Maćkowiak M. (2023). Psychedelics action and schizophrenia. Pharmacological reports : PR, 75(6), 1350–1361. https://doi.org/10.1007/s43440-023-00546-5
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2015). Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. Biological psychiatry, 78(8), 544–553. https://doi.org/10.1016/j.biopsych.2014.11.015
Holze, F., Ley, L., Müller, F., Becker, A. M., Straumann, I., Vizeli, P., Kuehne, S. S., Roder, M. A., Duthaler, U., Kolaczynska, K. E., Varghese, N., Eckert, A., & Liechti, M. E. (2022). Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology, 47(6), 1180–1187. https://doi.org/10.1038/s41386-022-01297-2
Martinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M. C., Lorusso, M., di Giannantonio, M., & Lerner, A. G. (2018). Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives. Brain sciences, 8(3), 47. https://doi.org/10.3390/brainsci8030047
Szafoni, S., Więckiewicz, G., Pudlo, R., Gorczyca, P., & Piegza, M. (2022). Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review. Czy psychoterapia wspomagana metylenodioksymetaamfetaminą (MDMA) okaże się przełomowa w terapii opornego na leczenie zespołu stresu pourazowego? Krytyczny przegląd narracyjny. Psychiatria polska, 56(4), 823–836. https://doi.org/10.12740/PP/OnlineFirst/133919
R., Lee, V. R., & Maguire, N. J. (2024, January 17). 3,4-Methylenedioxymethamphetamine (MDMA) toxicity. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK538482/
Pantoni, M. M., Kim, J. L., Van Alstyne, K. R., & Anagnostaras, S. G. (2022). MDMA and memory, addiction, and depression: dose-effect analysis. Psychopharmacology, 239(3), 935–949. https://doi.org/10.1007/s00213-022-06086-9
Azadbakht, A. A., Mashayekhi-Sardoo, H., & Baghcheghi, Y. (2025). Molecular Mechanisms Underlying Chronic High-Dose Ketamine-Induced Apoptosis in the Hippocampus: A Narrative Review. Neurochemical research, 51(1), 7. https://doi.org/10.1007/s11064-025-04619-0
Kaye, A. D., Wolf, M. C., Dufour, S. I., Haynes, A. T., Potharaju, P., Shekoohi, S., & Ahmadzadeh, S. (2025). Efficacy of Ketamine Infusion for Treatment of Opioid Use Disorder in Patients with Chronic Pain: a Narrative Review. Current Pain and Headache Reports, 30(1). https://doi.org/10.1007/s11916-025-01437-5
Danyon J. Anderson , Jessica Zhou , David Cao , Matthew McDonald , Maya Guenther , Jamal Hasoon , Omar Viswanath , Alan D. Kaye , Ivan Urits . Ketamine-Induced Cystitis: A Comprehensive Review of the Urologic Effects of This Psychoactive Drug. HPR 2022, 10(3), 1. https://doi.org/10.52965/001c.38247
Al-Garni, A. M., Vazquez, G., Alotibi, T., Hernandorena, C., & Knyahnytska, Y. (2026). Efficacy and safety of ketamine maintenance therapy in treatment-resistant depression: A systematic review of treatment protocols and clinical outcomes. Journal of affective disorders, 394(Pt A), 120475. https://doi.org/10.1016/j.jad.2025.120475
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Adam Wolski, Ewa Szplit, Mikołaj Patalong, Roman Cemaga, Mateusz Kubicki, Przemysław Kołodziej, Natalia Bruska, Bartłomiej Błaszkowski, Andrii Bilyk, Katarzyna Więckowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 9
Number of citations: 0
